Workboat Indexes
Latest News about BMY
Recent news which mentions BMY
Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
February 06, 2024
From Benzinga
Bristol-Myers Squibb Options Trading: A Deep Dive into Market Sentiment
February 05, 2024
Tickers
BMY
From Benzinga
Undervalued Gems: 7 Stocks Set for a Major Rebound
February 05, 2024
From InvestorPlace
Bristol Myers Squibb (BMY) Q4 2023 Earnings Call Transcript
February 02, 2024
Tickers
BMY
From Motley Fool
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
From Benzinga
What's Going On With US Pharma Giant Bristol-Myers Squibb Stock Today?
February 02, 2024
From Benzinga
Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year
February 02, 2024
From Benzinga
Earnings Scheduled For February 2, 2024
February 02, 2024
From Benzinga
Investor Optimism Improves Following Earnings, Economic Reports; Dow Jumps Over 350 Points
February 02, 2024
From Benzinga
Amazon, Apple And 3 Stocks To Watch Heading Into Friday
February 02, 2024
From Benzinga
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
January 30, 2024
From Benzinga
Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts?
January 30, 2024
From Benzinga
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients
January 29, 2024
From Benzinga
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
From Benzinga
3 Healthcare Stocks at 52-Week Lows: Buy or Bye?
January 26, 2024
From InvestorPlace
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer'
January 24, 2024
From Benzinga
7 Beaten-Down Value Stocks Poised for an Epic Turnaround
January 23, 2024
From InvestorPlace
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
January 23, 2024
From Benzinga
Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup
January 23, 2024
From Benzinga
From Benzinga
Bristol Myers' Lead Cancer Immunotherapy Shows Progression Free Survival Versus Chemo In Certain Type Of Colorectal Cancer
January 22, 2024
From Benzinga
Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes
January 19, 2024
From Benzinga
Inflation-Busting Price Hikes For Ozempic, Mounjaro And Others: Are Drugmakers Profiteering?
January 18, 2024
From Benzinga
Behind the Scenes of Bristol-Myers Squibb's Latest Options Trends
January 16, 2024
Tickers
BMY
From Benzinga
Financial Relief For Medicare Patients: Part D Overhaul Caps Out-of-Pocket Drug Cost Limits
January 16, 2024
From Benzinga
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
January 12, 2024
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.